Hives therapy developer Third Harmonic Bio units phrases for proposed $153M IPO

Date:


IPO Initial Public Offering

Mikko Lemola

Third Harmonic Bio (THRD) has set phrases for a proposed $153M preliminary public providing.

The biotech firm stated in a submitting that it’s taking a look at providing 9M shares priced between $16 and $18, which might increase round $153M if priced on the midpoint.

Underwriters could be granted an choice to purchase as much as 1.4M extra shares to cowl any overallotments. Morgan Stanley, Jefferies and Cowen are serving as lead bookrunners. Third Harmonic hopes to listing its shares on Nasdaq beneath the image THRD.

Based mostly in Cambridge, Mass., Third Harmonic’s lead product, THB001, is a KIT inhibitor being developed as a doable therapy for power uticaria, also referred to as hives.

The biotech group is at present working within the purple. For 2021, it reported a internet lack of $30M and no income.

Final month, Third Harmonics stated it was trying to increase round $150M.

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Share post:

Popular

More like this
Related